Axio Biosolutions

medical devices

About

Axio Biosolutions is a medical technology company founded in 2008 by bio-engineer Leo Mavely. The company specializes in advanced wound care and bleeding control solutions, focusing on affordable and impactful products for emerging markets. Axio develops innovative biomaterial-based medical devices aimed at managing trauma, surgical, and chronic wounds. The flagship product, Axiostat, is a patented haemostatic dressing made from 100% pure-grade chitosan. It effectively controls moderate to severe bleeding in pre-hospital trauma and surgical settings. Axiostat is USFDA 510(k) cleared and European CE approved. Another product, MaxioCel, is designed for acute and chronic wounds, promoting faster healing and reducing pain. Axio Biosolutions serves hospitals, trauma care providers, and healthcare institutions, aiming to improve patient outcomes through their products. Headquartered in Cambridge, Massachusetts, with roots in India, the company is ISO 13485 certified and supported by investors like Accel Partners and IDG Ventures.

Technologies

GmailGoogle AppsAdobe Media OptimizerGoogle Font APIVimeoWordPress.orgYouTubeGoogle Tag ManagerMobile FriendlyCedexis RadarGoogle Analytics

Keywords

medical deviceswound care managementchitosanbiomaterialshaemostatbleeding controlaxiostatmaxiocelhealthcaredefensehospitalsmedicalhealth careenterprise softwaresoftwareinformation technologymedical equipment manufacturingpressure sore managementclinical validationregulatory approvalchronic wound managementwound management in emergency settingstrauma care productsbiopolymer wound carepressure ulcer healingchronic woundspainless dressing removalhemorrhage controlwound careregulatory approvals in multiple countries

Location

Sanand, Gujarat, India, 382213

Related Companies

Companies in the same industry